CHURC1 Activators
CHURC1 activators comprise a spectrum of chemical compounds that orchestrate a variety of intracellular signaling events leading to the enhanced functional activity of CHURC1. Forskolin, for instance, by elevating cAMP levels within the cell, indirectly stimulates CHURC1 through the activation of PKA, which is known to phosphorylate proteins that could associate with CHURC1's regulatory mechanisms. This cascade of phosphorylation events can potentiate CHURC1's role in cellular processes. Similarly, Ionomycin, by increasing intracellular calcium concentration, triggers calcium-dependent kinases which may interact with CHURC1 or its functional partners, thus facilitating CHURC1's activity. Phorbol 12-myristate 13-acetate (PMA) and S-Nitroso-N-acetylpenicillamine (SNAP) further diversify the activation landscape by engaging PKC and soluble guanylyl cyclase pathways, respectively. The activation of these kinases by PMA and the elevation of cGMP levels by SNAP can lead to phosphorylation events that indirectly enhance CHURC1 function through signaling interplay.
The intricate network of CHURC1 activation is further complemented by compounds like Isoproterenol and Rolipram, which increase cAMP levels, and Anisomycin, which, besides inhibiting protein synthesis, activates JNK - a kinase that could phosphorylate substrates involved in CHURC1's pathway. LY294002 and PD98059 act on PI3K and MEK pathways, respectively, and their inhibitory actions can lead to altered phosphorylation patterns that indirectly augment CHURC1 activity. SB203580 modifies cellular responses by specifically inhibiting p38 MAPK, indirectly affecting CHURC1 signaling. Moreover, Tetrodotoxin, a sodium channel blocker, and Okadaic Acid, a protein phosphatase inhibitor, contribute to the regulation of CHURC1 activity through their effects on neuronal signaling and protein phosphorylation states. These chemicals, by modulating diverse signaling pathways, collectively enhance the functional activity of CHURC1 without direct binding interactions or transcriptional regulation of the CHURC1 gene.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, increasing intracellular levels of cAMP. Elevated cAMP activates PKA (protein kinase A), which can then phosphorylate various substrates, including proteins that may interact with or regulate CHURC1, enhancing its functional activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. The rise in calcium can activate calcium-dependent signaling pathways, which might include kinases or other proteins that could phosphorylate CHURC1 or proteins associated with CHURC1's function, enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC). Activated PKC phosphorylates target proteins that could potentially include substrates involved in the same pathways as CHURC1, thereby indirectly enhancing CHURC1 activity by promoting related signaling processes. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels by activating adenylyl cyclase via the beta-adrenergic receptor. The subsequent PKA activation could enhance CHURC1 functional pathways through phosphorylation of associated proteins. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which breaks down cAMP. Inhibiting PDE4 leads to increased cAMP levels and subsequent PKA activation, potentially enhancing CHURC1's activity by modulating signaling pathways that intersect with CHURC1 function. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that also activates stress-activated protein kinases (SAPKs) like JNK. Activation of JNK could lead to phosphorylation events in signaling cascades that enhance CHURC1's activity by altering its interaction with other cellular proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can modulate downstream signaling pathways such as Akt. Altering this pathway can lead to modifications in signaling cascades that intersect with CHURC1's activity, potentially enhancing its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that can lead to alterations in the MAPK/ERK pathway. By modulating this pathway, PD98059 could induce changes in protein phosphorylation patterns that indirectly enhance CHURC1 activity through interconnected signaling networks. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By selectively inhibiting p38 MAPK, it changes the dynamics of cellular stress responses and cytokine signaling, which can have a downstream effect on CHURC1 activity by modifying its related signaling pathways. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A. By inhibiting these phosphatases, it can lead to increased phosphorylation levels within the cell, potentially affecting proteins that regulate or interact with CHURC1, enhancing CHURC1's functional activity. | ||||||